Clinical and laboratory data of the whole sample (n=68)
| Patients’ features | Values |
| Age, years* | 34 (22–42) |
| BMI* | 22.9 (16.4–31.2) |
| Prothrombin time, INR* | 0.95 (0.9–1.1) |
| Activated partial thromboplastin time, ratio* | 0.94 (0.8–1.2) |
| Blood group, O vs non-O | 29/39 |
| Thrombophilia yes, n (%) | 7 (10.3)† |
| Gravidity* | 2 (1–7) |
| Parity* | 0 (0–6) |
| Previous GVCs/vein thrombosis | 14/3 |
| Previous CS, n | 15 |
| Index pregnancy | |
| LMWH/aspirin, n | 19/5 |
| GVCs | 2 |
| Cesarean section, n (%) | 27 (39.7) |
| Vaginal delivery, n (%) | 41 (60.3) |
| Gestational weeks at delivery* | 38 (33–41) |
| Birth weight*, g | 3295 (1600–4100) |
| Newborn sex, male/female | 26/42 |
*Values are provided as median and (range).
†Five women were factor V Leiden and 2 prothrombin mutation heterozygous carriers.
BMI, body mass index; CS, cesarean section; GVC, gestational vascular complication; INR, international normalized ratio; LMWH, low-molecular-weight heparin.